Methylene blue (MB) is the first‐line treatment for symptomatic acute toxic methemoglobinemia, especially when methemoglobin levels exceed 30%, due to its rapid and well‐established effectiveness. The gene discussed is HBG2; the disease is methemoglobinemia.